These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32038957)

  • 61. Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma.
    Li Z; Yang W; Qiu J; Xu H; Fan B; Li K; Zhou J; Li Y
    J Cancer; 2021; 12(22):6640-6655. PubMed ID: 34659554
    [No Abstract]   [Full Text] [Related]  

  • 62. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Overexpression of PKMYT1 Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell Carcinoma.
    Chen P; Zhang Z; Chen X
    Med Sci Monit; 2020 Oct; 26():e926755. PubMed ID: 33024069
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of the Prognostic Values of the CXCR1-7 in Clear Cell Renal Cell Carcinoma (ccRCC) Microenvironment.
    Wu Z; Zhang Y; Chen X; Tan W; He L; Peng L
    Front Mol Biosci; 2020; 7():601206. PubMed ID: 33324682
    [No Abstract]   [Full Text] [Related]  

  • 65. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, Western blotting, and immunohistochemistry.
    Han D; Yu Z; Zhang H; Liu H; Wang B; Qian D
    Bioengineered; 2021 Dec; 12(2):10891-10904. PubMed ID: 34845968
    [TBL] [Abstract][Full Text] [Related]  

  • 66. VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma.
    Lkhagvadorj S; Oh SS; Lee MR; Jung JH; Chung HC; Cha SK; Eom M
    J Lifestyle Med; 2014 Mar; 4(1):64-70. PubMed ID: 26064856
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Extended Opioid Exposure Modulates the Molecular Metabolism of Clear Cell Renal Cell Carcinoma.
    Garige M; Poncet S; Norris A; Chou CK; Wu WW; Shen RF; Greenberg JW; Krane LS; Sourbier C
    Life (Basel); 2023 May; 13(5):. PubMed ID: 37240841
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases.
    Pan Q; Wang L; Chai S; Zhang H; Li B
    J Cancer; 2020; 11(11):3207-3215. PubMed ID: 32231726
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma.
    Mou Y; Zhang Y; Wu J; Hu B; Zhang C; Duan C; Li B
    Front Oncol; 2020; 10():788. PubMed ID: 32528886
    [No Abstract]   [Full Text] [Related]  

  • 71. Identification of biomarkers related to CD8
    Lin J; Yu M; Xu X; Wang Y; Xing H; An J; Yang J; Tang C; Sun D; Zhu Y
    Aging (Albany NY); 2020 Feb; 12(4):3694-3712. PubMed ID: 32081834
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development and Validation of a Clinical Prognostic Model Based on Immune-Related Genes Expressed in Clear Cell Renal Cell Carcinoma.
    Ren S; Wang W; Shen H; Zhang C; Hao H; Sun M; Wang Y; Zhang X; Lu B; Chen C; Wang Z
    Front Oncol; 2020; 10():1496. PubMed ID: 32983989
    [No Abstract]   [Full Text] [Related]  

  • 73. Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Ye J; Chu C; Zuo L; Zhang J; Cui X
    Cell Death Differ; 2021 Mar; 28(3):932-951. PubMed ID: 33009518
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
    Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
    Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overexpression of LINC00160 predicts poor outcome and promotes progression of clear cell renal cell carcinoma.
    Cheng G; Yu Y; Wang L; Pan Q
    Aging (Albany NY); 2020 Apr; 12(8):7448-7464. PubMed ID: 32315986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of significant genes with prognostic influence in clear cell renal cell carcinoma via bioinformatics analysis.
    Zhang F; Wu P; Wang Y; Zhang M; Wang X; Wang T; Li S; Wei D
    Transl Androl Urol; 2020 Apr; 9(2):452-461. PubMed ID: 32420151
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The SLC Family Are Candidate Diagnostic and Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma.
    Kang W; Zhang M; Wang Q; Gu D; Huang Z; Wang H; Xiang Y; Xia Q; Cui Z; Jin X
    Biomed Res Int; 2020; 2020():1932948. PubMed ID: 32461965
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The pattern and prognostic relevance of immune activity scores and tumor-infiltrating immune cells in metastatic clear cell renal cell carcinoma: Evidence from multiple datasets.
    Shi B; Qi J
    Int Immunopharmacol; 2020 Aug; 85():106651. PubMed ID: 32505901
    [TBL] [Abstract][Full Text] [Related]  

  • 79. LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment.
    Dong X; Gu DN; Wang O; Ye Z
    Int Immunopharmacol; 2020 Oct; 87():106793. PubMed ID: 32683301
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.